{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:23:47Z","timestamp":1792783427059,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100015223","name":"Danish Diabetes and Endocrine Academy","doi-asserted-by":"publisher","award":["OL8201"],"award-info":[{"award-number":["OL8201"]}],"id":[{"id":"10.13039\/100015223","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007460","name":"Arvid Nilssons Fond","doi-asserted-by":"publisher","award":["Dok1780631"],"award-info":[{"award-number":["Dok1780631"]}],"id":[{"id":"10.13039\/100007460","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012526","name":"Sundhedsvidenskabelige Fakultet, Aarhus Universitet","doi-asserted-by":"publisher","award":["phd0115"],"award-info":[{"award-number":["phd0115"]}],"id":[{"id":"10.13039\/100012526","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007405","name":"Hjerteforeningen","doi-asserted-by":"publisher","award":["15-r99-a5947-22032"],"award-info":[{"award-number":["15-r99-a5947-22032"]}],"id":[{"id":"10.13039\/100007405","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Kirsten Anthonius Memorial Fund"},{"DOI":"10.13039\/501100010983","name":"Health Research Fund of Central Denmark Region","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010983","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004954","name":"Augustinus Fonden","doi-asserted-by":"publisher","award":["15-4919"],"award-info":[{"award-number":["15-4919"]}],"id":[{"id":"10.13039\/501100004954","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003035","name":"Aase og Ejnar Danielsens Fond","doi-asserted-by":"publisher","award":["10-001657"],"award-info":[{"award-number":["10-001657"]}],"id":[{"id":"10.13039\/501100003035","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006308","name":"Helga og Peter Kornings Fond","doi-asserted-by":"publisher","award":["55027-100"],"award-info":[{"award-number":["55027-100"]}],"id":[{"id":"10.13039\/501100006308","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007438","name":"Familien Hede Nielsens Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007438","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Aarhus University Hospital","id":[{"id":"https:\/\/ror.org\/040r8fr65","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"DOI":"10.1007\/s40262-026-01699-1","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T10:20:54Z","timestamp":1790590854000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Metformin Pharmacogenetics in Heart Failure Patients with Reduced Ejection Fraction: Impact on Metformin and Growth Differentiation Factor-15 Plasma Levels"],"prefix":"10.1007","clinical-trial-number":[{"clinical-trial-number":"nct02797340","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1127-6910","authenticated-orcid":false,"given":"Anders Hostrup","family":"Larsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tore Bjerregaard","family":"Stage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette Marie Hougaard","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren","family":"Feddersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flemming","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene","family":"N\u00f8rrelund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rgen","family":"Fr\u00f8ki\u00e6r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Jessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Br\u00f8sen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Wiggers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"issue":"5\u20136","key":"1699_CR1","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s10557-017-6754-x","volume":"31","author":"SL Kristensen","year":"2017","unstructured":"Kristensen SL, Jhund PS, Lee MMY, Kober L, Solomon SD, Granger CB, et al. Prevalence of prediabetes and undiagnosed diabetes in patients with HFpEF and HFrEF and associated clinical outcomes. Cardiovasc Drugs Ther. 2017;31(5\u20136):545\u20139.","journal-title":"Cardiovasc Drugs Ther"},{"key":"1699_CR2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.115.002560","author":"SL Kristensen","year":"2016","unstructured":"Kristensen SL, Preiss D, Jhund PS, Squire I, Cardoso JS, Merkely B, et al. Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial. Circ Heart Fail. 2016. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.115.002560.","journal-title":"Circ Heart Fail"},{"issue":"6","key":"1699_CR3","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.jchf.2019.12.015","volume":"8","author":"M Vaduganathan","year":"2020","unstructured":"Vaduganathan M, Fonarow GC, Greene SJ, DeVore AD, Kavati A, Sikirica S, et al. Contemporary treatment patterns and clinical outcomes of comorbid diabetes mellitus and HFrEF: the CHAMP-HF Registry. JACC Heart failure. 2020;8(6):469\u201380.","journal-title":"JACC Heart failure."},{"issue":"9","key":"1699_CR4","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1016\/j.biocel.2013.06.022","volume":"45","author":"F Staud","year":"2013","unstructured":"Staud F, Cerveny L, Ahmadimoghaddam D, Ceckova M. Multidrug and toxin extrusion proteins (MATE\/SLC47); role in pharmacokinetics. Int J Biochem Cell Biol. 2013;45(9):2007\u201311.","journal-title":"Int J Biochem Cell Biol"},{"issue":"12","key":"1699_CR5","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/j.bcp.2005.09.011","volume":"70","author":"J M\u00fcller","year":"2005","unstructured":"M\u00fcller J, Lips KS, Metzner L, Neubert RH, Koepsell H, Brandsch M. Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochem Pharmacol. 2005;70(12):1851\u201360.","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"1699_CR6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2165\/11534750-000000000-00000","volume":"50","author":"GG Graham","year":"2011","unstructured":"Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong J, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 2011;50(2):81\u201398.","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"1699_CR7","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1124\/dmd.107.015495","volume":"35","author":"M Zhou","year":"2007","unstructured":"Zhou M, Xia L, Wang J. Metformin transport by a newly cloned proton-stimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine. Drug Metab Dispos. 2007;35(10):1956\u201362.","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"1699_CR8","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1097\/FPC.0b013e32834c0010","volume":"21","author":"MM Christensen","year":"2011","unstructured":"Christensen MM, Brasch-Andersen C, Green H, Nielsen F, Damkier P, Beck-Nielsen H, et al. The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenet Genomics. 2011;21(12):837\u201350.","journal-title":"Pharmacogenet Genomics"},{"issue":"9","key":"1699_CR9","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1007\/s00125-017-4335-y","volume":"60","author":"JC Florez","year":"2017","unstructured":"Florez JC. The pharmacogenetics of metformin. Diabetologia. 2017;60(9):1648\u201355.","journal-title":"Diabetologia"},{"issue":"2","key":"1699_CR10","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/sj.clpt.6100275","volume":"83","author":"Y Shu","year":"2008","unstructured":"Shu Y, Brown C, Castro R, Shi R, Lin E, Owen R, et al. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther. 2008;83(2):273\u201380.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"1699_CR11","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/clpt.2009.92","volume":"86","author":"M Tzvetkov","year":"2009","unstructured":"Tzvetkov M, Vormfelde S, Balen D, Meineke I, Schmidt T, Sehrt D, et al. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin Pharmacol Ther. 2009;86(3):299\u2013306.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"1699_CR12","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/clpt.2008.61","volume":"84","author":"I Song","year":"2008","unstructured":"Song I, Shin H, Shim E, Jung I, Kim W, Shon J, et al. Genetic variants of the organic cation transporter 2 influence the disposition of metformin. Clin Pharmacol Ther. 2008;84(5):559\u201362.","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"1699_CR13","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1097\/FPC.0b013e328302cd41","volume":"18","author":"Z-J Wang","year":"2008","unstructured":"Wang Z-J, Yin OQ, Tomlinson B, Chow MS. OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenet Genomics. 2008;18(7):637\u201345.","journal-title":"Pharmacogenet Genomics"},{"issue":"7","key":"1699_CR14","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/FPC.0b013e32832cc7e9","volume":"19","author":"Y Chen","year":"2009","unstructured":"Chen Y, Li S, Brown C, Cheatham S, Castro RA, Leabman MK, et al. Effect of genetic variation in the organic cation transporter 2, OCT2, on the renal elimination of metformin. Pharmacogenet Genomics. 2009;19(7):497.","journal-title":"Pharmacogenet Genomics"},{"issue":"2","key":"1699_CR15","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/clpt.2012.210","volume":"93","author":"SL Stocker","year":"2013","unstructured":"Stocker SL, Morrissey KM, Yee SW, Castro RA, Xu L, Dahlin A, et al. The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin. Clin Pharmacol Ther. 2013;93(2):186\u201394.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"1699_CR16","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s00228-015-1853-8","volume":"71","author":"MMH Christensen","year":"2015","unstructured":"Christensen MMH, H\u00f8jlund K, Hother-Nielsen O, Stage TB, Damkier P, Beck-Nielsen H, et al. Steady-state pharmacokinetics of metformin is independent of the OCT1 genotype in healthy volunteers. Eur J Clin Pharmacol. 2015;71(6):691\u20137.","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"1699_CR17","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1097\/FPC.0000000000000133","volume":"25","author":"TB Stage","year":"2015","unstructured":"Stage TB, Damkier P, Pedersen RS, Christensen MM, Christiansen L, Christensen K, et al. A twin study of the trough plasma steady-state concentration of metformin. Pharmacogenet Genomics. 2015;25(5):259\u201362.","journal-title":"Pharmacogenet Genomics"},{"issue":"2","key":"1699_CR18","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3892\/br.2024.1806","volume":"21","author":"A Ortega-Ayala","year":"2024","unstructured":"Ortega-Ayala A, De Andr\u00e9s F, Llerena A, Bartolo-Montiel CM, Molina-Guarneros JA. Impact of SLC22A1 variants rs622342 and rs72552763 on HbA1c and metformin plasmatic concentration levels in patients with type 2 diabetes mellitus. Biomed Rep. 2024;21(2):117.","journal-title":"Biomed Rep."},{"issue":"11","key":"1699_CR19","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1111\/dme.13098","volume":"33","author":"D Boucaud-Maitre","year":"2016","unstructured":"Boucaud-Maitre D, Ropers J, Porokhov B, Altman JJ, Bouhanick B, Doucet J, et al. Lactic acidosis: relationship between metformin levels, lactate concentration and mortality. Diabet Med. 2016;33(11):1536\u201343.","journal-title":"Diabet Med"},{"key":"1699_CR20","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1002\/ejhf.1656","volume":"22","author":"AH Larsen","year":"2019","unstructured":"Larsen AH, Jessen N, Norrelund H, Tolbod LP, Harms HJ, Feddersen S, et al. A randomised, double-blind, placebo-controlled trial of metformin on myocardial efficiency in insulin-resistant chronic heart failure patients without diabetes. Eur J Heart Fail. 2019;22:1628\u201337.","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"1699_CR21","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s10557-020-07050-5","volume":"35","author":"AH Larsen","year":"2021","unstructured":"Larsen AH, Wiggers H, Dollerup OL, Jespersen NR, Hansson NH, Fr\u00f8ki\u00e6r J, et al. Metformin lowers body weight but fails to increase insulin sensitivity in chronic heart failure patients without diabetes: a randomized, double-blind, placebo-controlled study. Cardiovasc Drugs Ther. 2021;35(3):491\u2013503.","journal-title":"Cardiovasc Drugs Ther"},{"key":"1699_CR22","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ahj.2020.09.020","volume":"231","author":"H Wiggers","year":"2021","unstructured":"Wiggers H, K\u00f8ber L, Gislason G, Schou M, Poulsen MK, Vraa S, et al. The DANish randomized, double-blind, placebo controlled trial in patients with chronic heart failure (DANHEART): a 2 \u00d7 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chronic heart failure and diabetes or prediabetes (Met-HeFT). Am Heart J. 2021;231:137\u201346.","journal-title":"Am Heart J"},{"issue":"12","key":"1699_CR23","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1038\/s42255-019-0146-4","volume":"1","author":"EA Day","year":"2019","unstructured":"Day EA, Ford RJ, Smith BK, Mohammadi-Shemirani P, Morrow MR, Gutgesell RM, et al. Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight loss. Nat Metab. 2019;1(12):1202\u20138.","journal-title":"Nat Metab"},{"issue":"7795","key":"1699_CR24","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/s41586-019-1911-y","volume":"578","author":"AP Coll","year":"2020","unstructured":"Coll AP, Chen M, Taskar P, Rimmington D, Patel S, Tadross JA, et al. GDF15 mediates the effects of metformin on body weight and energy balance. Nature. 2020;578(7795):444\u20138.","journal-title":"Nature"},{"issue":"2","key":"1699_CR25","doi-asserted-by":"publisher","DOI":"10.1111\/ijpo.12845","volume":"17","author":"G Carreras-Badosa","year":"2022","unstructured":"Carreras-Badosa G, G\u00f3mez-Vilarrubla A, Mas-Par\u00e9s B, Mart\u00ednez-Calcerrada JM, Xargay-Torrent S, Prats-Puig A, et al. A 24-month metformin treatment study of children with obesity: changes in circulating GDF-15 and associations with changes in body weight and visceral fat. Pediatr Obes. 2022;17(2):e12845.","journal-title":"Pediatr Obes"},{"issue":"1","key":"1699_CR26","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/ejhf.3078","volume":"26","author":"JP Ferreira","year":"2024","unstructured":"Ferreira JP, Packer M, Butler J, Filippatos G, Pocock SJ, Januzzi JL, et al. Growth differentiation factor-15 and the effect of empagliflozin in heart failure: findings from the EMPEROR program. Eur J Heart Fail. 2024;26(1):155\u201364.","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"1699_CR27","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/cpt.567","volume":"101","author":"T Dujic","year":"2017","unstructured":"Dujic T, Zhou K, Yee SW, van Leeuwen N, de Keyser CE, Javorsk\u00fd M, et al. Variants in pharmacokinetic transporters and glycemic response to metformin: a Metgen meta-analysis. Clin Pharmacol Ther. 2017;101(6):763\u201372.","journal-title":"Clin Pharmacol Ther"},{"key":"1699_CR28","doi-asserted-by":"publisher","first-page":"1183879","DOI":"10.3389\/fpubh.2023.1183879","volume":"11","author":"A Peng","year":"2023","unstructured":"Peng A, Gong C, Xu Y, Liang X, Chen X, Hong W, et al. Association between organic cation transporter genetic polymorphisms and metformin response and intolerance in T2DM individuals: a systematic review and meta-analysis. Front Public Health. 2023;11:1183879.","journal-title":"Front Public Health"},{"issue":"7","key":"1699_CR29","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1111\/dom.13264","volume":"20","author":"LJ McCreight","year":"2018","unstructured":"McCreight LJ, Stage TB, Connelly P, Lonergan M, Nielsen F, Prehn C, et al. Pharmacokinetics of metformin in patients with gastrointestinal intolerance. Diabetes Obes Metab. 2018;20(7):1593\u2013601.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"1699_CR30","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1086\/428594","volume":"76","author":"M Stephens","year":"2005","unstructured":"Stephens M, Scheet P. Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. Am J Hum Genet. 2005;76(3):449\u201362.","journal-title":"Am J Hum Genet"},{"issue":"4","key":"1699_CR31","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1086\/319501","volume":"68","author":"M Stephens","year":"2001","unstructured":"Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet. 2001;68(4):978\u201389.","journal-title":"Am J Hum Genet"},{"issue":"21","key":"1699_CR32","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1001\/archinte.163.21.2594","volume":"163","author":"SR Salpeter","year":"2003","unstructured":"Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med. 2003;163(21):2594\u2013602.","journal-title":"Arch Intern Med"},{"issue":"1","key":"1699_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-04056-7","volume":"15","author":"M Shahzad","year":"2025","unstructured":"Shahzad M, Ahmed S, Ahsan M, Zulfiqar E, Hurjkaliani S, Thakur T, et al. Trends and disparities in heart failure mortality with and without chronic kidney disease in a nationwide retrospective analysis. Sci Rep. 2025;15(1):29103.","journal-title":"Sci Rep"},{"issue":"3","key":"1699_CR34","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1161\/CIRCHEARTFAILURE.112.000162","volume":"6","author":"DT Eurich","year":"2013","unstructured":"Eurich DT, Weir DL, Majumdar SR, Tsuyuki RT, Johnson JA, Tjosvold L, et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circ Heart Fail. 2013;6(3):395\u2013402.","journal-title":"Circ Heart Fail"},{"issue":"39","key":"1699_CR35","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","volume":"44","author":"N Marx","year":"2023","unstructured":"Marx N, Federici M, Sch\u00fctt K, M\u00fcller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043\u2013140.","journal-title":"Eur Heart J"},{"issue":"8","key":"1699_CR36","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1111\/bcp.15737","volume":"89","author":"G Chowdhury","year":"2023","unstructured":"Chowdhury G, Carland JE, Kumar S, Olsen N, Graham G, Kumarasinghe G, et al. The safe use of metformin in heart failure patients both with and without T2DM: a cross-sectional and longitudinal study. Br J Clin Pharmacol. 2023;89(8):2603\u201313.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1699_CR37","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/bcpt.13139","volume":"124","author":"TB Stage","year":"2019","unstructured":"Stage TB, Wellhagen G, Christensen MMH, Guiastrennec B, Br\u00f8sen K, Kjellsson MC. Using a semi-mechanistic model to identify the main sources of variability of metformin pharmacokinetics. Basic Clin Pharmacol Toxicol. 2019;124(1):105\u201314.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"2","key":"1699_CR38","doi-asserted-by":"publisher","first-page":"94","DOI":"10.2165\/00003088-198815020-00002","volume":"15","author":"FV Shammas","year":"1988","unstructured":"Shammas FV, Dickstein K. Clinical pharmacokinetics in heart failure. An updated review. Clin Pharmacokinet. 1988;15(2):94\u2013113.","journal-title":"Clin Pharmacokinet."},{"issue":"1","key":"1699_CR39","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/bcp.13760","volume":"85","author":"AA Mangoni","year":"2019","unstructured":"Mangoni AA, Jarmuzewska EA. The influence of heart failure on the pharmacokinetics of cardiovascular and non-cardiovascular drugs: a critical appraisal of the evidence. Br J Clin Pharmacol. 2019;85(1):20\u201336.","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"1699_CR40","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1007\/s00125-015-3733-2","volume":"58","author":"MM Christensen","year":"2015","unstructured":"Christensen MM, Hojlund K, Hother-Nielsen O, Stage TB, Damkier P, Beck-Nielsen H, et al. Endogenous glucose production increases in response to metformin treatment in the glycogen-depleted state in humans: a randomised trial. Diabetologia. 2015;58(11):2494\u2013502.","journal-title":"Diabetologia"},{"issue":"8","key":"1699_CR41","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s40262-015-0270-6","volume":"54","author":"TB Stage","year":"2015","unstructured":"Stage TB, Br\u00f8sen K, Christensen MM. A comprehensive review of drug-drug interactions with metformin. Clin Pharmacokinet. 2015;54(8):811\u201324.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"1699_CR42","doi-asserted-by":"publisher","first-page":"280","DOI":"10.2337\/dc16-1682","volume":"40","author":"HC Gerstein","year":"2017","unstructured":"Gerstein HC, Pare G, Hess S, Ford RJ, Sjaarda J, Raman K, et al. Growth differentiation factor 15 as a novel biomarker for metformin. Diabetes Care. 2017;40(2):280\u20133.","journal-title":"Diabetes Care"},{"issue":"3","key":"1699_CR43","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.026003","volume":"12","author":"MS Binder","year":"2023","unstructured":"Binder MS, Yanek LR, Yang W, Butcher B, Norgard S, Marine JE, et al. Growth differentiation factor-15 predicts mortality and heart failure exacerbation but not ventricular arrhythmias in patients with cardiomyopathy. J Am Heart Assoc. 2023;12(3):e8023.","journal-title":"J Am Heart Assoc"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01699-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01699-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01699-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T10:20:57Z","timestamp":1790590857000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-026-01699-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":43,"alternative-id":["1699"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01699-1","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"26 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Disclosures","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Anders Hostrup Larsen, Tore Bjerregaard Stage, Mette Marie Hougaard Christensen, S\u00f8ren Feddersen, Flemming Nielsen, J\u00f8rgen Fr\u00f8ki\u00e6r, Niels Jessen, Kim Br\u00f8sen, and Henrik Wiggers declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Anders Hostrup Larsen, Torre Bjerregaard Stage, Mette Marie Hougaard Christensen, Helene N\u00f8rrelund, J\u00f8rgen Fr\u00f8ki\u00e6r, Niels Jessen, Kim Br\u00f8sen, and Henrik Wiggers contributed to the study conception, design, and study conduct. All authors contributed to data collection, analysis, and interpretation. All authors critically reviewed all manuscript drafts, approved the submitted version of the manuscript, and made the decision to submit the manuscript for publication.","order":3,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The datasets generated during and\/or analysed during the current study are available from the corresponding author on reasonable request.","order":4,"name":"Ethics","label":"Data availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients provided written informed consent in accordance with the principles of the Helsinki Declaration.","order":5,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was performed in accordance with Good Clinical Practice guidelines and was approved by the local scientific ethical committee of the Central Denmark Region, by the Danish Data Protection Agency, and by the Danish Medicines Agency.","order":6,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":8,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No AI tools were used.","order":9,"name":"Ethics","label":"AI use","group":{"name":"EthicsHeading","label":"Declarations"}}]}}